Q-omics provides the consensus-scored DHX57 profile across patient tissues and cancer cell-line models. DHX57 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, DHX57 is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, DHX57 protein abundance shows 25,148 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight MESO, and LUAD as cancer lineages where DHX57 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DHX57 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DHX57 survival associations across molecular data types. DHX57 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DHX57 RNA expression–survival associations across cancer types. High DHX57 expression shows unfavorable associations in MESO, LIHC, ACC and KICH, but favorable associations in KIRC and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for DHX57 RNA expression.
This table summarizes DHX57 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DHX57. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DHX57 shows lower tumor expression in THCA and higher tumor expression in LUAD, HNSC, LIHC, BLCA and COAD. The LUAD box plot shows higher DHX57 RNA expression in tumor versus normal tissue (log2 FC = +1.038, t-test p < 0.001).
This table shows molecular features associated with DHX57 in patient tissues and cancer cell lines. In patient samples, DHX57 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, DHX57 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
